Literature DB >> 9048400

The risk of venous thromboembolism in the orthopedic patient: epidemiological and physiological data.

G D Paiement1, C Mendelsohn.   

Abstract

Venous thromboembolism is responsible for 500,000 deaths annually in industrialized countries. It is probably the most common preventable cause of death in elective orthopedic surgery patients. Rates of deep vein thrombosis (DVT) and fatal pulmonary embolism (PE) in unprotected orthopedic patient populations are high. The overall DVT rate is > 40% in patients undergoing hip or knee arthroplasty or suffering from multiple injuries. The proximal DVT rate for these patients is > or = 15%, and the fatal PE rate is > or = 1%. Risk factors associated with venous thromboembolism are related to the vascular injury, activation of blood coagulation, and venous stasis. Lower extremity orthopedic procedures carry a risk greater than that of surgery itself. Thus, orthopedic patients are at high risk for venous thromboembolic conditions. A systematic assessment of this risk should be performed in every patient, and an appropriate management plan should be implemented.

Entities:  

Mesh:

Year:  1997        PMID: 9048400

Source DB:  PubMed          Journal:  Orthopedics        ISSN: 0147-7447            Impact factor:   1.390


  5 in total

1.  Incidence of deep venous thrombosis in Chinese patients undergoing arthroscopic knee surgery for cruciate ligament reconstruction.

Authors:  Jiang-tao Dong; Xin Wang; Xiao-qian Men; Xiao-feng Wang; Xiao-zuo Zheng; Shi-jun Gao
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2014-11-02       Impact factor: 4.342

2.  Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing.

Authors:  Katia Sindali; Barry Rose; Hassan Soueid; Parminder Jeer; Deepak Saran; Raj Shrivastava
Journal:  Eur J Orthop Surg Traumatol       Date:  2012-04-17

3.  Utility of once-daily dose of low-molecular-weight heparin to prevent venous thromboembolism in multisystem trauma patients.

Authors:  C Clay Cothren; Wade R Smith; Ernest E Moore; Steven J Morgan
Journal:  World J Surg       Date:  2007-01       Impact factor: 3.352

4.  Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen.

Authors:  Dagmar Kubitza; Michael Becka; Wolfgang Mueck; Michael Zuehlsdorf
Journal:  Br J Clin Pharmacol       Date:  2006-11-13       Impact factor: 4.335

5.  Safety and efficacy of a new thromboprophylaxis regiment for total knee and total hip replacement: a retrospective cohort study in 265 patients.

Authors:  Mohammad Amre Fallaha; Sarkhell Radha; Sheena Patel
Journal:  Patient Saf Surg       Date:  2018-08-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.